



Public Offering only in: CH Participation Products SSPA Product Type: 1300 TCM-Collateralised Products

Termsheet

## **Tracker Certificate on USD LWC AI Index**

Open End; issued in USD; listed on SIX Swiss Exchange

ISIN CH1491776352 | Swiss Security Number 149177635 | SIX Symbol AEXRTQ

This Product is collateralised in accordance with the terms and conditions of the TCM Security Agreement for Triparty Collateral Management Products ("TCM Products"). More detailed information regarding the collateralisation can be found in the section "Information about TCM-Collateralisation" below.

Investors should read the section "Significant Risks" below as well as the section "Risk Factors" of the relevant Issuance and Offering Programme, as amended from time to time. By investing in this product (the "Product"), the Investor may put the capital that he invested in this Product at risk and, in addition, transaction costs may incur. Investors may lose some or all of their capital invested in the Product as well as the transaction costs. Investors are exposed to the credit risk of the Issuer.

Even though translations into other languages might be available, only the English version of the Final Terms or Pricing Supplement and the relevant Issuance and Offering Programme are legally binding.

The Investor's exposure to the credit risk of the Issuer is only mitigated due to collateralization.

#### For Switzerland

This Product is a derivative instrument according to Swiss law. It does not qualify as unit of a collective investment scheme pursuant to articles 7 et seqq. of the Swiss Federal Act on Collective Investment Schemes ("CISA") and is therefore neither registered nor supervised by the Swiss Financial Market Supervisory Authority ("FINMA"). Investors do not benefit from the specific investor protection provided under the CISA. This document constitutes advertising within the meaning of article 68 of the Swiss Federal Act on Financial Services ("FinSA"). This document is a termsheet prepared in view of the issuance of the Products and neither a prospectus within the meaning of articles 35 et seqq. of the FinSA, nor a private placement documentation, nor a key information document according to articles 58 et seqq. of the FinSA or any equivalent document under the FinSA. The information contained in this document is not complete and is subject to completion and amendment. This document has neither been reviewed nor approved by a reviewing body pursuant to articles 51 et seqq. FinSA. This document does not, and is not intended to, constitute or contain an offer or invitation to sell, and it is not soliciting offers to buy, the Product in any jurisdiction where such offer or sale is not permitted.

#### **Product Description**

The Tracker Certificate (the "Certificate") replicates the price movements in the Underlying (adjusted by the Units, the Management Fee, the Performance Fee, the Calculation Agent Fee, the Collateral Fee any expenses and taxes, and, as the case may be, the FX Rate) and is therefore in terms of risk comparable to a direct investment in the Underlying. At the Redemption Date, the Investor will receive a Cash Settlement in the Settlement Currency, as further described under Redemption.

#### **Index Description**

The Underlying is a dynamic, actively managed index (the "Index") which is discretionarily managed by the Index Sponsor and calculated by the Index Calculation Agent. The components of the Underlying (the "Components") may – subject to Index Calculation Agent's veto right – be rebalanced by the Index Sponsor on a regular basis. The Index Sponsor determines and is responsible for the composition of the Index and may add, replace or remove Components in accordance with a set of predefined rules set out in the Index Rule Book "USD LWC AI Index", Version ID 9PR1V. dated 29/10/2025 (the "Index Rule Book").

Objective: The AI LWC AMC is designed to capture opportunities in the AI-led economy by investing in the shares of companies at the forefront of technological transformation. With a long-term investment horizon, the strategy seeks to benefit from structural growth trends rather than short-term market fluctuations. The portfolio is built on high conviction and maintains a concentrated focus on only the strongest ideas. Positions are reviewed and rebalanced quarterly, maintaining alignment with evolving market conditions and the underlying investment thesis. The allocation is actively managed, with an AI overlay integrated into the decision-making process to complement traditional portfolio management with advanced, data-driven insights.

Universe: The Index universe consists of eligible Components and may include Cash Instruments, Shares, ETFs, Listed Options, as determined by the Index Sponsor and subject to the restrictions defined in the Index Rule Book.

Distributions: Net distributions with respect to Components (after deduction of any expenses and taxes) will lead to an adjustment of the Index (as specified in the Index Rule Book).

The Index represents a hypothetical portfolio. There is no obligation on the Index Calculation Agent, the Issuer or any other party to purchase and/or hold any Components of the Index and there is no actual portfolio of assets to which any person is entitled or in which any person has any ownership interest. The Index is merely comprised of Components, the performance of which will be used as a reference point for the purposes of calculating the value of the Index. The Issuer shall be free to choose how to invest or further proceed with any proceeds of the issuance of any of the Certificates.

References to any rebalancing of the Index or addition, adjustment, substitution, replacement or removal of Components should not be construed as imposing an obligation on the Issuer, the Index Calculation Agent or any person actually to acquire or dispose of any securities, investments, assets or other property but are references to the change in, and relate solely to the calculation of, the value of the Index, which is relevant for the determination of any amount payable in respect of the Certificate.

Upon request, the Index Rule Book and the latest composition of the Index are available free of charge from the Lead Manager (Leonteq Securities AG, Europaallee 39, 8004 Zurich, Switzerland or termsheet@leonteq.com).

UNDERLYING						
Underlying	Index Sponsor	Index Calculation Agent	Units <sub>0</sub>	Initial FX Rate (FX Rate <sub>0</sub> )	Currency	Initial Fixing Level (100%)* (Index Value <sub>0</sub> )
USD LWC AI Index	Little Whale Capital SA	Leonteq Securities AG	1.00000	1.00000	USD	USD 1000.0000

<sup>\*</sup> levels are expressed in percentage of the Initial Fixing Level

#### PRODUCT DETAILS

 Swiss Security Number
 149177635

 ISIN
 CH1491776352

 SIX Symbol
 AEXRTQ

 Issue Price
 USD 1'000.00

Issue Size 10'000 Certificate(s) (can be increased at any time)

Settlement Currency USD

DATES

 Initial Fixing Date
 29/10/2025

 Issue Date
 12/11/2025

Observation Dates Quarterly, from (and including) 31/12/2025; if a specific Observation Date is not a Scheduled Trading Day then the

following Scheduled Trading Day will be deemed to be an Observation Date.

First Exchange Trading Date 12/11/2025 (anticipated)

Last Trading Day/Time Open-end, or in the case of an exercise of the Issuer's Termination Right or the Investor's Termination Right, two

Scheduled Trading Days prior to the Final Fixing Date

Final Fixing Date

Open-end or, in case of an exercise of the Issuer's Termination Right, as specified in the Issuer's Termination

Announcement, or, in case of an exercise of the Investor's Termination Right, the date on which the exercise of such Investor's Termination Right becomes effective (as indicated in the section "Investor's Termination Right") (subject to

Market Disruption Event provisions)

Redemption Date

Open-End or in case of an exercise of the Issuer's Termination Right, as specified in the Issuer's Termination

Announcement, or, in case of an exercise of the Investor's Termination Right, the 5th business day following the Final

Fixing Date (subject to Settlement Disruption Event provisions)

FEES

**Distribution Fee**No Distribution Fees

Management Fee (MF) 0.70% p.a

The Management Fee reduces the redemption amount subject to the holding period and has a negative effect on the

secondary market prices. The Management Fee will be paid quarterly on the Observation Dates.

Calculation Agent Fee (CAF) 0.15% p.a.

The Calculation Agent Fee reduces the redemption amount subject to the holding period and has a negative effect on

the secondary market prices. The Calculation Agent Fee will be paid quarterly on the Observation Dates.

Collateral Fee (CF) 0.15% p.a. (Calculation Agent)

The Collateral Fee reduces the redemption amount subject to the holding period and has a negative effect on the

secondary market prices. The Collateral Fee will be paid quarterly on the Observation Dates.

**Performance Fee (PF)** 20.00% (fee split: 20.00% Index Sponsor, 0.00% Calculation Agent)

The Performance Fee reduces the redemption amount subject to the holding period and has a negative effect on the

secondary market prices. The Performance Fee will be paid quarterly on the Observation Dates.

**Rebalancing Fee**A Rebalancing Fee is levied by the Index Calculation Agent inside the Index for each Component adjustment within

the Index. The Rebalancing Fee represents a percentage amount of up to 0.05% of the notional volume of each of the transactions in the Components. Component adjustments exceeding a certain number per calendar year may be subject

to increased Rebalancing Fees.

For the avoidance of doubt, the Rebalancing Fee does not apply to changes in  $\mathsf{Units}_\mathsf{t}$  in the  $\mathsf{Underlying}$ . Market charges,

such as e.g. stamp duty or execution costs incurred by a hypothetical hedging entity as determined by the Index Calculation Agent in its discretion, will always be charged in addition to the Rebalancing Fee.

Calculation Agent in its discretion, will always be charged in addition to the nebalancing Fee.

Other fees Additional fees may be charged within individual Components (e.g. structured products) as outlined in the product

documentation of the relevant Component available from the Index Sponsor upon request. Such fees may also be paid

to the Issuer and/or to third parties such as the Index Sponsor.

#### REDEMPTION

The Investor is entitled to receive from the Issuer, subject to an Extraordinary Termination, on the Redemption Date per Product a Cash Settlement in the Settlement Currency corresponding to the value of the Underlying on the Final Fixing Date adjusted by the Units, the Management Fee, the Performance Fee, the Calculation Agent Fee, the Collateral Fee and, as the case may be, the FX Rate. This amount equals Value, on the Final Fixing Date, where Value, is calculated according to the following formula and reasonably determined by the Calculation Agent.

Value, = FX Rate, X Units, X Index Value, - AMF, - APF, - ACAF, - ACF,

Index Value<sub>t</sub> Means the official closing price of the Underlying on Scheduled Trading Day t as published by the Index Calculation

Agent, and as reasonable determined by the Calculation Agent.

 $\textbf{FX Rate}_{\textbf{t}} \qquad \qquad \text{Means the prevailing exchange rate on the Scheduled Trading Day t as reasonably determined by the Calculation Agent.}$ 

 $The \ exchange \ rate \ is \ expressed \ as \ units \ of \ the \ Settlement \ Currency \ per \ one \ unit \ of \ currency \ of \ the \ Underlying \ (if \ both \ underlying)$ 

currencies are identical then FX Rate<sub>t</sub> is equal to 1.0).

Units<sub>t</sub> Means the notional units of the Underlying per Product on Scheduled Trading Day t. Provided Scheduled Trading Day

t is not an Observation Date:

 $Units_t = Units_{t-1}$ 

If Scheduled Trading Day t is an Observation Date:

## Units, = Units, - (AMF, + APF, + ACAF, + ACF,) / (Index Value, x FX Rate,)

Where Index Value<sub>1\*</sub> means Index Value<sub>1</sub> of the Underlying on Scheduled Trading Day t, adjusted by any costs incurred by the Issuer or a hedging party thereof for unwinding risk reducing hedging transactions relating to the Issuer's obligations under the Product, as reasonable determined by the Calculation Agent. Units, are rounded in accordance with the Rounding Convention.

Following the adjustment of Units, by AMF, AMF, is reset to zero. Following the adjustment of Units, by ACAF, ACAF, is reset to zero. Following the adjustment of Units, by ACF, ACF, is reset to zero. Following the adjustment of Units, by APF, APF, is reset to zero.

Means the accrued management fees on Scheduled Trading Day t and is determined by the Calculation Agent as

 $AMF_t = AMF_{t-1} + Value_{t-1} \times MF \times DayCount_t \text{ and } AMF_0 = 0.00$ 

Means the accrued calculation agent fees on Scheduled Trading Day t and is determined by the Calculation Agent as ACAF,

follows:

 $ACAF_t = ACAF_{t-1} + Value_{t-1} \times CAF \times DayCount_t$  and  $ACAF_0 = 0.00$ 

ACF<sub>t</sub> Means the accrued collateral fees on Scheduled Trading Day t and is determined by the Calculation Agent as follows:

 $\label{eq:acft} \text{ACF}_t = \text{ACF}_{t\text{-}1} + \text{Value}_{t\text{-}1} \ x \ \text{CF} \ x \ \text{DayCount}_t \ \text{and} \ \text{ACF}_0 = 0.00$ 

Day Count, Means the actual number of calendar days between (and including) Scheduled Trading Day t-1 to (and excluding) the

current Scheduled Trading Day t divided by 360.

**Rounding Convention** Numbers are rounded down to five (5) decimal places.

Means the accrued performance fees on Scheduled Trading Day t and is determined by the Calculation Agent as follows: APF<sub>t</sub>

 $APF_t = APF_{t-1} + PF \times Max(0; Value_{t-1} - Watermark_{t-1})$  and  $Watermark_0 = Watermark_1 = Index Value_0$  and  $APF_0 = APF_{t-1} + PF \times Max(0; Value_{t-1} - Watermark_{t-1})$ 

Watermark<sub>t</sub> Max(Watermark<sub>t-1</sub>; Value<sub>t-1</sub>)

Scheduled Trading Day t Means any calendar day on which the Index Calculation Agent is scheduled to publish a value for the Underlying. The Initial Fixing Date corresponds to Scheduled Trading Day 0 and for any subsequent Scheduled Trading Day variable t

is incremented by one (1.0).

**Initial Fixing Level** (Index Value,)

AMF,

Means the official closing price of the Underlying on the Initial Fixing Date as determined by the Calculation Agent.

**Extraordinary Termination** 

The Issuer has the right to call all Certificates with immediate effect, without prior notice (the "Extraordinary Termination"). Such Extraordinary Termination will prevail any Investor's Termination Right and/or Issuer's Termination Right, if applicable.

The Issuer may exercise its right for Extraordinary Termination:

a. based on Hedging Disruption and other provisions as set out in paragraph "Termination and Cancellation due to Illegality, Impracticality, Illiquidity, Impossibility, Increased Cost of Hedging, Hedging Disruption, Increased Cost of Collateralisation (TCM Products and ETPs), Changed Secured Financing Ability, Negative Value or Materially Increased Other Costs" of the Programme: or

b. if the agreement, or any part thereof concerning the Index, between the Index Sponsor and the Issuer and/or the Index Calculation Agent (or an affiliate thereof) is terminated; or

c. if the Index in whole or the calculation of the index value are terminated, as the case may be.

In case of an Extraordinary Termination the Issuer will pay to the Investor a Cash Settlement in the Settlement Currency that shall be the fair market value of the Product, taking into account the event that led to the Extraordinary Termination, less any costs and withholdings levied onto the Issuer and/or any of its affiliates for unwinding its hedge positions, all as determined by the Calculation Agent in its discretion. Such amount shall be paid to the Investor 5 Business Days following completion and receipt in full of the proceeds for all disinvestments in all relevant hedge positions, as reasonably determined by the Calculation Agent in its discretion.

**Issuer's Termination Right** 

The Issuer has the right to call all Certificates for early redemption (the "Termination Right") at any time with a 15 Business Days (prior to the respective Final Fixing Date) notice by announcement (the "Termination Announcement") on the Lead Manager's website, all in accordance with the General Terms and Conditions of the Programme. The Termination Announcement will specify the Final Fixing Date and the respective Redemption Date. Following the announcement, the Certificates will be redeemed on the Redemption Date for a value equal to the Value, on the Final Fixing Date as determined by the Calculation Agent.

Investor's Termination Right Each Investor has an annual right, on 29/10 and for the first time on 29/10/2026, to call the Certificates for redemption (such day the Investor's Termination Right becomes effective being the Final Fixing Date, as defined herein) by delivering a duly completed and signed Redemption Notice to the Paying Agent in accordance with the General Terms and Conditions of the Programme (the Redemption Notice to be received by the Paying Agent no later than 12:00 am CET on the 15th Business Day preceding the respective Final Fixing Date). Thereafter, the Certificates will be redeemed on the Redemption Date for a value equal to the Value, on the Final Fixing Date as determined by the Calculation Agent.

# GENERAL INFORMATION

Leonteq Securities AG, Guernsey Branch, St Peter Port, Guernsey Issuer

(Rating: Fitch BBB- with stable outlook, Supervisory Authority: FINMA / GFSC)

**Collateral Provider (TCM)** Leonteq Securities AG, Guernsey Branch, St Peter Port, Guernsey

Leonteq Securities AG, Zurich, Switzerland Lead Manager **Calculation Agent** Leonteg Securities AG, Zurich, Switzerland Leonteg Securities AG, Zurich, Switzerland **Paying Agent** 

Little Whale Capital SA, 50 Chemin Frank Thomas Cologny, C/O Charles Abou Eid, Cologny 1223, Switzerland. The Index Sponsor

Index Sponsor is supervised by: FINMA Swiss Financial Markets Supervisory Authority.

SIX Swiss Exchange AG; traded on SIX Swiss Exchange - Structured Products Listing/Exchange

> There is no obligation of the Issuer and/or the Lead Manager or any third party to list the Product or apply for admission to trading at issuance or during the term of the Product. In case of a listed/admitted Product, there is no obligation to

maintain a listing/admission during the term of the Product.

**Secondary Market** Daily price indications will be available from 09:15 - 17:15 CET on www.leonteq.com, Refinitiv [SIX Symbol]=LEOZ or

[ISIN]=LEOZ and Bloomberg [ISIN] Corp or on LEOZ.

Products may only be sold to a third party with the prior consent of the Lead Manager and only in form of a private Resale

placement. Thus, Investors must contact the Lead Manager before they resell the Products.

**Quotation Type** Secondary market prices are quoted in the Settlement Currency, per Product.

Settlement Type(s) Cash Settlement Minimum Investment 1 Certificate(s) **Minimum Trading Lot** 1 Certificate(s) **Minimum Redemption** 1 Certificate(s) Number

**Maximum Redemption** 

Number

1 Certificate(s)

Clearing SIX SIS Ltd, Euroclear, Clearstream

Depository SIX SIS Ltd **Public Offering only in** Switzerland Private Placement in N/A

**Uncertificated Securities** 

Governing Law / Jurisdiction Swiss / Zurich

The definition "Issuing Party/Parties" as used herein, means the Issuer, as indicated in section "General Information".

## TAXATION SWITZERLAND

Swiss Federal Stamp Duty For Swiss stamp duty purpose, the Product is treated as analogous to a share/unit in a foreign investment fund. Therefore, primary and secondary market transactions are in principle subject to Swiss stamp duty (TK24).

tax domicile in Switzerland)

Swiss Federal Income Tax For Swiss income tax purpose, the Product is treated as analogous to a share/unit in an investment fund. Any reinvested (for private investors with dividend and interest income from the Underlying are subject to income tax. The taxable income (if any) earned by the Product is annually reported to the Swiss Federal Tax Administration. For private Investors with tax domicile in Switzerland holding the Product as part of their private property, the reported income (if any) is subject to the Federal Direct Tax.

> In the absence of tax reporting, taxable income is determined based on a fair market return, taking into account the asset classes of the Underlying.

> Any dividend payments are subject to the Federal Direct Tax on the respective payment date. The tax treatment regarding the cantonal and communal income taxes can differ from the tax treatment regarding the Federal Direct Tax. But in general the income tax treatments are corresponding.

**Swiss Withholding Tax** 

The Product is not subject to Swiss withholding tax.

The tax information provided herein is a non-binding summary and only provides a general overview of the potential Swiss tax consequences linked to this Product at the time of issue. Tax laws and tax interpretation may change at any time, possibly with retroactive effect.

Investors and prospective Investors are advised to consult with their tax advisers with respect to the Swiss tax consequences of the purchase, ownership, disposition, lapse or exercise or redemption of a Product in light of their particular circumstances. The Issuing Parties and the Lead Manager hereby expressly exclude any liability in respect of any possible tax implications.

# Information with regards to FATCA (Foreign Account Tax Compliance Act)

Any payment under this Product may be subject to withholding tax (such as, inter alia, withholding related to FATCA or 871(m) of the US Tax Code). Any payments due under this Product are net of such tax. If an amount in respect of Section 871(m) of the U.S. Tax Code were to be deducted or withheld from interest, principal or other payments on the Products, none of the Issuer, any Paying Agent or any other person would be required to pay additional amounts as a result of the deduction or withholding of such tax, i.e. the Investor would receive a significant lower amount than he would have received without such deduction or withholding.

# PRODUCT DOCUMENTATION

It is intended that the Products will be issued under a base prospectus as per article 45 FinSA, which has been approved by SIX Exchange Regulation AG ("SIX Exchange Regulation") in its capacity as Swiss Prospectus Office. Only the relevant final terms (the "Final Terms"), which will be available no later than on the Issue Date, together with the base prospectus of the relevant Issuance and Offering Programme (the "Programme") dated 17 June 2025, as supplemented from time to time (the "Base Prospectus") shall form the entire and legally binding documentation for the Products (the "Product Documentation", and the Final Terms, together with the applicable terms and conditions for the relevant Product, "Conditions"). The Final Terms will be registered with SIX Exchange Regulation in its capacity as Swiss Prospectus Office. The Final Terms should always be read together with the Base Prospectus. Definitions used in this Termsheet, but not defined herein, shall have the meaning given to them in the Final Terms and the Base Prospectus. Even though a translation into other languages might be available, only the English version of the Final Terms jointly with the Base Prospectus are legally binding.

A key information document in accordance with Regulation (EU) No 1286/2014 (the "PRIIPs KID") or a key information document in accordance with FinSA (the "FinSA KID") has been prepared in relation to the Products. The PRIIPs KID can be obtained in electronic form on www.priipkidportal.com or upon request and free of charge from the Lead Manager. The FinSA KID can be obtained upon request and free of charge from the Lead Manager. Other regulatory documents, including the target market assessment, are also available, or can be requested, from the same source.

Notices to Investors in connection with the Products shall be validly given in accordance with the Conditions. Notices to investors relating to the Issuer or the Guarantor (if any) will be published on www.leonteq.com and/or on the web page of the Guarantor (if any), respectively.

During the whole term of the Products, the Product Documentation can be ordered free of charge from the Lead Manager Leonteq Securities AG, Europaallee 39, CH-8004 Zurich (Switzerland), by phone (+41 58 800 1111)\*, fax (+41 (0)58 800 10 10) or by e-mail (termsheet@leonteq.com). Please note that all calls made to numbers marked with an asterisk (\*) are recorded. By calling such number, your consent to the recording is deemed given.

#### SIGNIFICANT RISKS

Prospective Investors should ensure that they fully understand the nature of this Product and the extent of their exposure to risks and they should consider the suitability of this Product as an investment in the light of their own circumstances and financial condition. Products involve a high degree of risk, including the potential risk of expiring worthless. Potential Investors should be prepared in certain circumstances to sustain a total loss of the capital invested to purchase this Product as well as the transaction costs. Prospective Investors shall consider the following important risk factors and read the section "Risk Factors" of the Programme for details on all other risk factors to be considered.

This is a structured product involving derivative components. Investors should make sure that their advisors have verified that this Product is suitable for their portfolio taking into account the investor's financial situation, investment experience and investment objectives.

The terms and conditions of the Product may be subject to adjustments during the lifetime of the Product as set out in the Programme.

**Product Specific Risks**: Unless this Product provides for full repayment of capital, investors may lose some or all of their investment as well as the transaction costs as they are fully exposed to the performance of the Underlyings. The Product does not confer any claim to receive rights and/or payments of the Underlying, such as dividend payments, unless explicitly stated in the documentation governing the Product. Please refer to the Product Documentation as regards the further Product specific risk factors to be taken into account.

**Index Administration Specific Risks**: The Product provides exposure to a discretionary Index managed by the Index Sponsor. The Index Sponsor has a significant scope of discretion in terms of the Index' composition and will determine the initial composition of the Index and subsequent adjustments thereof, excluding adjustments and substitutions made by the Index Calculation Agent in accordance with the Index Rule Book or as defined herein and save where a rebalancing request of the Index Sponsor has been declined by the Index Calculation Agent. The performance of the Index and hence of the Product depends, inter alia, on the quality of the Index Sponsor's decisions as regards the composition of the Index (excluding adjustments and substitutions made by Index Calculation Agent in accordance with the Index Rule Book or as defined herein). Investors need to do their own due diligence with respect to the Index Sponsor.

Index Performance: Neither the Calculation Agent nor the Index Calculation Agent take any responsibility for the composition of, adjustment (excluding adjustments not due to a Non-Compliance Event and substitutions made by Index Calculation Agent in accordance with the Index Rule Book or as defined herein) to and the performance of the Index. Unless required by applicable laws and regulations, neither the Calculation Agent nor the Index Calculation Agent are obliged to verify compliance with the index rules set out in the Index Rule Book or to intervene in case of non-compliance with the index rules set out in the Index Rule Book.

Diversification of the Index: If there are no minimum diversification criteria for the Index, as defined in the Index Rule Book, the Underlying may comprise of one single Component.

**Issuer Risk**: Investors are exposed to the credit risk of the Issuer. If the Issuer is not able to make a payment or becomes insolvent, investors could lose some or all of their investment.

**Credit Risk of Issuing Parties**: The Investor's exposure to the credit risk of the Issuer of this Product is only mitigated due to collateralisation. In order to collateralize this Product, collateral is being deposited at SIX SIS Ltd. Following a so called Realization Event, e.g. in case of insolvency of the Issuer, the deposited securities will be used for the Redemption of the Product. For further information please see the section "Information about TCM-Collateralisation" below.

**Secondary Market**: The Issuer and/or the Lead Manager or any third party appointed by the Issuer, as applicable, intends, under normal market conditions, to provide bid and offer prices for the Products on a regular basis in accordance with the SIX Directive on Debt Securities with Specific Structures. However, the Issuer and/or the Lead Manager, as applicable, reserve the right to cease the posting of bid and offer prices upon the occurrence and for the duration of any exceptional market circumstances. In special market situations, where the Issuer and/or the Lead Manager is/are unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices may be temporarily expanded, in order to limit the economic risks of the Issuer and/or the Lead Manager.

**Market Risk**: Market risk may have a negative impact on the value of and the return on an investment in the Product. Market risk is the risk associated with the effect of changes in market factors such as interest and foreign exchange rates, equity and commodity prices, credit spreads or implied volatilities, on the value of assets and liabilities held for both the short and long term. Market risk may also lead to an early redemption of the Product (e.g. in the event of a hedging disruption).

**Liquidity Risk**: The Issuer or, as the case may be, the guarantor or a third party appointed by the Issuer or guarantor, if any, intends to act as market maker in relation to the Product and it will use commercially reasonable efforts to provide indicative bid and offer prices for the Product on a regular basis under normal market conditions. However, such market maker does not have an obligation to provide prices for the Product. Liquidity of the Product in the secondary market may be limited and an active trading market for the Product may not develop. Accordingly, investors may not be able to sell their Product.

**Currency Risk**: If the investor's reference currency is different from the currency, in which the Product is denominated, the investor bears the currency risk between the two currencies. The fluctuations in exchange rates could have an adverse effect on the value of or return on an investment in the Product, even if the redemption amount would otherwise provide for a positive return. If the Underlyings are calculated in a currency different from the Currency of the Product, the conversion into the Currency of the Product will be carried out at the relevant exchange rate.

Early Termination and Reinvestment Risk: The Product may be redeemed prior to its maturity (be it by declaration of the issuer or as a result of certain events specified in the terms of the Product) and investors must consider that in case of such an early redemption, investors will not receive any further coupon payments after the occurrence of the early redemption and the early redemption amount may be significantly below the issue / purchase price paid and the redemption amount payable at maturity. Investors may not be able to reinvest the early redemption amount in a financial instrument with the same profit potential and additional transaction costs may be incurred as a consequence of a reinvestment of the early redemption amount.

**Illiquidity of Underlying**: One or, if applicable, more of the Underlyings might be or become illiquid over the lifetime of the Product. Illiquidity of an Underlying might lead to larger bid/offer spreads of the Product and/or to an extended time period for buying and/or selling the Underlying respective to acquire, unwind or dispose of the hedging transaction(s) or asset(s) or to realise, recover or remit the proceeds of such hedging transaction(s) or

asset(s) which might implicate a postponed redemption or delivery and/or a modified redemption amount, as reasonably determined by the Calculation Agent.

# ADDITIONAL INFORMATION AND RISK FACTORS RELATED TO PRODUCTS LINKED TO A REFERENCE ASSET DENOMINATED IN RENMINBI AND RENMINBI-DENOMINATED PRODUCTS.

For the purpose of this Termsheet and where the context requires, "Renminbi" or "CNY" refers to the lawful currency of the People's Republic of China ("PRC"). "CNY" is the official (ISO) code on the currency markets. CNY is not available and not tradable outside of the PRC. Therefore "CNH" has been established as offshore deliverable CNY. CNH is not an official ISO code and is only used as a technical term for differentiation between the currency used/traded in the PRC (CNY) and the respective offshore tradable and deliverable currency (CNH).

Renminbi is subject to PRC exchange control policies and there is limited availability of Renminbi outside the PRC. Renminbi is not freely convertible and is subject to exchange control policies and restrictions of the PRC government. As a result of restrictions imposed by the PRC government on cross-border Renminbi fund flows, the availability of Renminbi outside the PRC is limited, which may adversely affect the liquidity of Renminbi outside the PRC, which in turn may adversely affect the market value, and the potential return, of the Product.

#### Risks relating to Renminbi exchange rate and interest rate

The Product will be denominated and settled in Renminbi outside the PRC. The exchange rate of, and interest rate for, Renminbi outside the PRC may be different from the same in the PRC. The value of Renminbi against Hong Kong dollar and other foreign currencies fluctuates and is affected by changes in the PRC and international political, economic and market conditions and by many other factors. There is no guarantee that Renminbi will not depreciate and any devaluation of Renminbi could adversely affect the market value of the Product. In addition, interest rates for Renminbi in the PRC are government controlled. The PRC government may further liberalise the regulation of interest rates for Renminbi in the PRC which may increase interest rate volatility for Renminbi outside the PRC. Any fluctuation in interest rates for Renminbi outside the PRC may adversely affect the market value, and the potential return, of the Product.

#### Renminbi payment risk

If the Settlement Currency of the Product is Renminbi, and a FX Disruption Event has occurred and is continuing on, a scheduled date of payment, payment may be made in Successor Currency on the postponed payment date. In such case, there may be a delay in payments under the Product and no interest will be payable for any such delay. Investors may also suffer a loss in the Successor Currency if Renminbi depreciates against the Successor Currency following the occurrence of a FX Disruption Event.

#### **China Connect risk**

If the Underlying(s) or Underlying Component(s) are eligible securities listed and traded on the SSE and SZSE ("China Connect Securities") (as in the case of A-Shares as Underlying), foreign investors may invest in such China Connect Securities through China Connect. The respective Hedging Entity may (but is not obliged to) choose to hedge obligations under the Products using China Connect.

Trading through China Connect is subject to a number of restrictions which may restrict or affect an investment in China Connect Securities, including (but not restricted to) the application of PRC law and regulation to investors in China Connect Securities, pre-trade checking to prevent naked short-selling, the application of aggregate and daily RMB quotas and restrictions on the ability of an investor to take up certain types of rights issuances through China Connect. In particular, it should be noted that China Connect is in its initial stages. Further developments are likely and there is no assurance as to whether or how such developments may restrict or affect an investment in China Connect Securities. In addition, the laws and regulations of Hong Kong and the PRC, and the rules, policies or guidelines published or applied by any regulator which regulates China Connect and activities relating to China Connect (including without limitation, the China Securities Regulatory Commission (CSRS), People's Bank of China (PBOC), State Administration of Foreign Exchange (SAFE), Securities and Futures Commission (SFC), Hong Kong Monetary Authority (HKMA) or any other regulator, agency or authority with jurisdiction, authority or responsibility in respect of China Connect), or any exchange, clearing system or other entity which provides services relating to China Connect (including without limitation, the Stock Exchange of Hong Kong (SEHK) and any relevant subsidiary, Hong Kong Securities Clearing Company (HKSCC), Shanghai Stock Exchange (SSE), Shenzhen Stock Exchange (SZSE) or China Securities Depository and Clearing Corporation (CSDCC) from time to time in respect of China Connect or any activities arising from China Connect are new and subject to change, and there may be uncertainty as to their interpretation and/or implementation.

These potential restrictions and uncertainties relating to China Connect may trigger a Hedging Disruption, a Market Disruption Event or an Additional Disruption Event. Even if trading on the SSE or SZSE continues uninterrupted, such events concerning China Connect could lead to adjustments to the terms of the Products or to their redemption earlier, or later, than scheduled. Such uncertainty and any potential change of the laws and regulations in the PRC for the China Connect may adversely impact on the performance of the Underlying and may also have a potential retrospective effect. These changes may in turn adversely affect the market value of the Product, which may result in a partial or total loss of the invested capital.

#### Risks of investing in the PRC securities market and derivative instruments relating to it

The PRC capital market is still at a premature stage. Regulation of the PRC capital market is heavily influenced by government policies and is less transparent and less efficient than the regulation of developed capital markets. There still remain allegations and convictions of malpractices such as market manipulation and insider trading. The stock price of a PRC listed company may not therefore reasonably reflect its intrinsic value. In addition, the disclosure of information by a PRC company with respect to its financial status may not always be complete and reliable. If the stock price of a PRC listed company does not reasonably reflect its intrinsic value, such pricing inaccuracy will be passed through to derivative instruments such as the Products

Investment in the PRC securities markets (which are inherently stock markets with restricted access) involves certain risks and special considerations as compared with investment in more developed economies or markets, such as greater political, tax, economic, foreign exchange, liquidity and regulatory risks.

# ADDITIONAL INFORMATION / DISCLAIMER

#### **Prudential Supervision**

Leonteq Securities AG is authorised as securities firm and subject to prudential supervision by FINMA. Leonteq Securities AG, Guernsey Branch is licensed by the Guernsey Financial Services Commission ("GFSC") to carry on the restricted activities of promotion, subscription, registration, dealing, management, administration and advising in respect of Category 2 (General Securities and Derivatives) controlled investments.

# Conflict of Interests

The Issuing Parties and/or the Lead Manager and/or any third party appointed by them, as the case may be, may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market as well as be active on both sides of the market at the same time in any securities, currencies, financial instruments or other assets underlying the products to which this document relates. The Issuer's and Lead Manager's and/or the appointed third party's trading and/or hedging activities related to this transaction may have an impact on the price of the Underlying and may affect the likelihood that any relevant Barrier Level, if any, is reached.

#### Remunerations to Third Parties

Depending on the circumstances the Issuer and/or Lead Manager may sell this Product to financial institutions or intermediaries at a discount to the Issue Price or reimburse a certain amount to such financial institutions or intermediaries (reference is made to section "General Information" herein). For open-end products such fees will be split linearly over ten years.

In addition, for certain services rendered by distribution partners and to increase quality and services relating to the Products, the Issuer and/or Lead Manager may from time to time pay recurring fees to such third parties.

Further information is available on request.

#### Payment of a Coupon

If the Product stipulates the Payment of a Coupon, the Investor is only entitled to receive the respective coupon payment, if he has purchased/not sold the Product at the latest on the Business Day preceding the respective Coupon Ex-Date for the then prevailing price.

#### No Offer

This Termsheet is primarily provided for information purposes and does not constitute a recommendation, an offer or a solicitation of an offer to buy financial products.

#### No Representation

The Issuer, the Lead Manager and any third party appointed by them make no representation or warranty relating to any information herein which is derived from independent sources.

#### **ESG**

The Product is not classified as sustainable. No representation as to the sustainability – within the meaning of Regulation (EU) 2020/852 (Taxonomy Regulation) and Regulation (EU) 2019/2088 (Sustainable Finance Disclosure Regulation) or any other sustainability-related law or regulation – of the Product or any Underlying is provided. Any reference to sustainability-related terms in relation to the Product or any Underlying shall not imply the provision of any such representation by the Issuer, the Lead Manager or the Guarantor, as applicable. It is furthermore specified that the Product is not aimed at clients with specific needs regarding sustainability preferences pursuant to Art. 2 No. 7 of the MiFID II Delegated Regulation (EU) 2017/565.

## INFORMATION ABOUT TCM-COLLATERALISATION

Triparty Collateral Management Products ("**TCM Products**") are structured products with a reduced issuer risk. This protection is provided by means of a collateral pledge.

The Collateral Provider has entered into a security agreement (as amended or replaced from time to time, the "**TCM Security Agreement**") and TCM Products are collateralised in accordance with the terms of the TCM Security Agreement. The Collateral Provider will provide collateral to secure the value of TCM Products, whereby such collateral can consist among others of the securities that are the direct or indirect underlyings of TCM Products.

The legal position of the Investors and of all involved parties in relation to the collateralisation of TCM Products is determined by the provisions of the TCM Security Agreement. The Issuer shall, upon request, provide the TCM Security Agreement to the Investors free of charge. A copy of the TCM Security Agreement may be obtained from the Lead Manager at Europaallee 39, 8004 Zurich (Switzerland), or via telephone (+41 58 800 1111\*), fax (+41-(0)58-8001010) or email (termsheet@leonteq.com). Please note that all calls made to numbers marked with an asterisk (\*) are recorded. By calling such number, your consent to the recording is deemed given.

More detailed information regarding TCM collateralisation can also be found in the Programme.

The costs with respect to the collateralisation of TCM Products as well as the borrowing costs of the products' collateral may be taken into account for the pricing of TCM Products and may therefore be borne by the Investors, as the case may be.

The payment to the Investors in case of a so-called Realisation Event may be delayed for factual or legal reasons.

To the extent the calculation of the current value of a TCM Product, as published daily by the Collateral Provider on SIX Financial Information, proves to be incorrect, the collateralisation of the TCM Product may be insufficient.

This TCM Product does not constitute a collective investment scheme pursuant to the Federal Act on Collective Investment Schemes (CISA) and does not require authorisation or supervision by the Swiss Financial Market Supervisory Authority FINMA.

#### SELLING RESTRICTIONS

No action has been or will be taken by the Issuer, the Guarantor (if any) or the Lead Manager, other than in Switzerland, to permit an offer of the Products or distribution of any offering material in relation to the Products to the public in any jurisdiction, where any such offer or distribution would require a prior permission. Any offer, sale or delivery of the Products, or distribution or publication of any offering material relating to the Products, in or from any jurisdiction may only be made in circumstances where no additional obligations are imposed on the Issuer, the Guarantor (if any) or the Lead Manager and in compliance with all applicable laws and regulations, including, without limitation, any restriction on cross-border business or communication related to the Products, and on making the Products available to persons subject to Sanctions or persons located, organised or resident in a Sanctioned Country. The Products may not be offered or sold within the United States or to, or for the account or benefit of US persons (as defined in Regulation S).

Detailed information on selling restrictions is available as part of the Base Prospectus which can be accessed in electronic form at www.leonteq.com and ordered free of charge from the Lead Manager. Further information on selling restrictions is available at https://ch.leonteq.com/legal/selling-restrictions. Such selling restrictions should not be taken as definitive guidance as to whether the Products may be offered, sold or advertised in any jurisdiction.